Welcome to our dedicated page for BIOMARIN PHARMACEUTICAL SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
BioMarin Pharmaceutical Inc. is asking stockholders to elect ten directors, ratify KPMG as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares reserved under the 2017 Equity Incentive Plan at its June 2, 2026 virtual annual meeting.
The proxy highlights 2025 revenue of $3.2 billion, up 13%, with VOXZOGO reaching $927 million. It describes an all-cash agreement to acquire Amicus Therapeutics for about $4.8 billion and the completed $270 million acquisition of Inozyme Pharma. The Board chair role will transition from Richard A. Meier to Ian T. Clark.
BioMarin Pharmaceutical Inc Schedule 13G/A (Amendment No. 12) updates The Vanguard Group's reporting following an internal realignment. The filing states amount beneficially owned: 0 and percent of class: 0%. The Vanguard Group explains certain subsidiaries will report separately in reliance on SEC Release No. 34-39538 dated January 12, 1998.
The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026.
BioMarin Pharmaceutical executive George Eric Davis, EVP and Chief Legal Officer, reported a routine share disposition related to taxes. On this date, 1,273 shares of common stock were withheld to cover tax obligations at $56.05 per share. After this tax-withholding transaction, he directly holds 78,560 shares of BioMarin common stock, indicating he retains a substantial equity position and that the filing reflects a compensation-related event rather than an open-market sale.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer reported a tax-related share disposition. On the transaction date, 1,693 shares of common stock were withheld at a price of $56.05 per share to cover tax obligations, a non‑market transaction. After this event, he directly held 84,140 common shares.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported a tax-related share disposition. On March 17, 2026, 2,117 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly holds 123,314 common shares, indicating a routine, non–market sale event.
BioMarin Pharmaceutical Chief Executive Officer Alexander Hardy reported a routine share disposition related to taxes. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly held 214,635 shares.
BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction. On March 16, 2026, she received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock at an exercise price of $57.43 per share. The option grant vests 12/48ths on March 16, 2027, with the remaining 36/48ths vesting in equal monthly installments of 1/48th on the 16th day of each month thereafter.
On March 17, 2026, 1,245 shares of Common Stock were disposed of at $56.05 per share in a tax-withholding transaction to satisfy tax obligations, rather than an open-market sale. After these transactions, Hubbard directly held 44,790 shares of BioMarin Common Stock.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg reported routine equity compensation and related tax withholding. On March 16, 2026, he received 19,150 shares of common stock as a grant and a stock option for 45,600 shares at a $57.43 exercise price, both held directly.
The restricted stock units were granted on March 16, 2026, and the option grant vests 12/48ths on March 16, 2027 and 1/48th monthly thereafter. On March 17, 2026, 1,629 shares of common stock were disposed of at $56.05 per share to cover tax obligations, leaving him with 55,099 common shares directly owned.
BioMarin Pharmaceutical executive Charles Greg Guyer reported new equity awards and a tax-related share withholding. On March 16, 2026 he received stock options for 35,680 shares of common stock at an exercise price of $57.43 per share, vesting over four years starting March 16, 2027.
He also received a grant of 14,990 shares of common stock, described in a footnote as restricted stock units granted on March 16, 2026 with no purchase price. On March 13, 2026, 9,109 shares of common stock were withheld at $58.51 per share to cover tax obligations, which is not an open-market sale. Following these transactions and a one-share clerical correction, he directly holds 85,833 shares of common stock.
BioMarin Pharmaceutical executive George Eric Davis reported new equity awards and related tax withholding. He received a stock option for 34,690 shares of common stock at an exercise price of $57.43 per share, vesting in part on March 16, 2027 and monthly thereafter until 2036.
He also received 14,570 restricted stock units on March 16, 2026, while 7,177 shares of common stock were withheld to cover tax obligations at $58.51 per share. After these transactions, Davis directly holds 79,833 shares of common stock.